Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of treating and preventing infections

A technology of microbial infection and quorum sensing, applied in the field of treatment or prevention of pathogenic bacterial infection, biofilm formation caused by oxidative stress in bacteria, can solve the negative impact of healthy vaginal microbiota and other issues

Inactive Publication Date: 2020-03-24
SCIENTELLE LLC
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, antibiotic therapy can lead to negative effects on healthy vaginal microbiota

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treating and preventing infections

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0114] Example 1: BPO at a low sub-MIC can be sufficient to interfere with the QS of G. vaginalis, control G. vaginalis and prevent this pathogen from reaching its virulence state.

[0115] Experimental details: In the first step of the experiment, a broth microdilution assay was used to determine the MIC and sub-MIC of BPO against G. vaginalis, the main microorganism responsible for bacterial vaginosis. A concentration of 250 μg / mL was established as a sub-MIC for G. vaginalis (in other words, BPO concentrations greater than 250 μg / mL were required to completely inhibit the growth of G. vaginalis) .

[0116] As a second step, the concentration that inhibits biofilm production is determined. Several BPO concentrations were tested: 0, 31.25, 62.5, 125 and 250 μg / mL. A colorimetric method was used for biofilm staining and determination of percent biofilm integrity after treatment.

[0117] Result: if figure 1 As shown, biofilm formation was inhibited by approximately 80% whe...

Embodiment 2

[0126] Example 2. Level 3 ROS. The goal of finding a therapeutically effective concentration of an antibacterial drug (indeed, any drug) cannot be achieved in preclinical studies (eg, in vitro or in vivo), and is always the subject of clinical studies (studies in humans). Briefly, different concentrations will be tested in humans for both therapeutic efficacy and safety (side effects), and the concentration deemed to be the best combination of efficacy and safety will be selected as the therapeutic concentration. FDA expects drug companies to demonstrate both ends of the antimicrobial spectrum: low / inadequate efficacy at the low end and indications of increased toxicity / compromised safety at the high end. In this example, potency at the low end of the antimicrobial spectrum has been identified, which is anomalous and very unusual. In practice, this would mean that, for example, for the treatment or prevention of bacterial vaginosis, a particular BPO-containing gel at a concen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Described are methods and pharmaceutical compositions for treating or preventing bacterial infections and other disease and conditions caused by bacterial imbalance or mediated via human microbiota. For example, described are pharmaceutical compositions comprising sub-minimum inhibitory concentrations of reactive oxygen species sufficient for arresting virulence through inhibition of quorum sensing, thereby modifying microbiota to a healthy state

Description

[0001] Cross References to Related Applications [0002] This application claims priority benefit to U.S. Provisional Patent Application 62 / 479,261 filed March 30, 2017, which is hereby incorporated by reference in its entirety for all purposes. Background technique [0003] 1. Discovery of technology areas. Methods and pharmaceutical compositions are described for treating or preventing bacterial infections and other diseases and conditions caused by bacterial imbalances or mediated by the human microbiota. For example, a method of reactive oxygen species (ROS) containing a subminimal inhibitory concentration (sub-MIC) sufficient to terminate virulence through quorum sensing inhibition, thereby altering the microbiota to a healthy state; i.e., the concentration of the MIC established below is described. pharmaceutical composition. [0004] 2. Background information. The emergence of multidrug-resistant pathogens and the prevalence of biofilm-associated infections have crea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/327A61K8/22A61P31/04A61Q17/00
CPCA61K9/0034A61K9/06A61K31/327A61K9/0014A61P31/04A61P1/00A61P17/06A61P19/02A61P29/00
Inventor 康斯坦丁·祖博夫斯基迈克尔·奇金达斯
Owner SCIENTELLE LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com